Sandbox Reserved 1109: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Undo revision 3144267 by Bachar Almazloum (Talk) |
No edit summary |
||
| Line 19: | Line 19: | ||
== Clinical Significance == | == Clinical Significance == | ||
Parkinson's disease (PD) is the most common neurodegenerative disorder affecting more than 10 Million Worldwide <ref>(https://www.parkinson.org/Understanding-Parkinsons/Statistics)</ref>. | α-synuclein can be described as an unstructured soluble protein, which lacks three-dimensional folding that proteins undergo after synthesis. Nevertheless, the clinical significance of α-synuclein protein lies behind the formation of insoluble fibrils characterized by Lewy bodies which can be found in Parkinson's disease (PD), dementia with Lewy bodies, multiple system atrophy <ref>doi:10.1007/s00401-002-0596-7,/ref>, as well as Alzheimer's disease. <ref>DOI:10.1007/s00401-002-0596-7</ref>. Moreover, Parkinson's disease is the most common neurodegenerative disorder affecting more than 10 Million Worldwide <ref>(https://www.parkinson.org/Understanding-Parkinsons/Statistics)</ref>. as discussed before, one of the main characteristics of Parkinson's disease is the aggregation of Lewy bodies. The aggregation mechanism of α-synuclein is still uncertain, however, there have been several hypotheses published in the literature.<ref>https://doi.org/10.1038/35081564</ref>. | ||
==Mechanism of aggregation== | ==Mechanism of aggregation== | ||
Parkinson's disease is characterized by the accumulation of Lewy bodies in the substantia nigra, a region in the midbrain responsible for motor control, where Lewy bodies contain a build-up of α-synuclein found within the cells that contribute to the disease <ref>PMID: 9546347</ref>. Lewy Bodies are cytoplasmic inclusion made of primarily α-synuclein protein, and may also contain other proteins such as; ubiquitin, Tau proteins. The structure of α-synuclein; N-terminal domain, C-terminal domain, and a hydrophobic core (NAC) suggests an aggregation pathway due to the unfolded nature of the protein. A recent study published by | Parkinson's disease is characterized by the accumulation of Lewy bodies in the substantia nigra, a region in the midbrain responsible for motor control, where Lewy bodies contain a build-up of α-synuclein found within the cells that contribute to the disease <ref>PMID: 9546347</ref>. Lewy Bodies are cytoplasmic inclusion made of primarily α-synuclein protein, and may also contain other proteins such as; ubiquitin, Tau proteins. The structure of α-synuclein; N-terminal domain, C-terminal domain, and a hydrophobic core (NAC) suggests an aggregation pathway due to the unfolded nature of the protein. A recent study published by Science Translational Medicine Journal, suggests that a covalent modification such as Serine-129 phosphorylation in α-synuclein, as well as hydrophobic interactions specifically located at the NAC domain of α-synuclein, allows for the polymerization of different α-synuclein protein into an anti-parallel β-sheet conformation permitting the formation of fibrils. Another hypothesis suggests the role of α-synuclein in the loss of dopaminergic neurons functions in PD, which is mediated through the formation of the 54-83 KD complex that contains aggregates of α-synuclein and 14-3-3 protein, which inhibits BCL-BAD protein complex responsible for the inhibition of Apoptosis in dopamine neurons in the midbrain. <ref>https://doi.org/10.1038/s41420-018-0125-7</ref><ref>doi: 10.1126/scitranslmed.3002566</ref> All in all, it is important to know that the pathway discussed above is one of many hypotheses for the role of α-synuclein in Parkinson's Disease (PD). | ||
== Relevance == | == Relevance == | ||
Besides being of key importance in reducing the degeneration caused due to the loss of CSPα, the α-synuclein is also believed to be related to various other proteins that regulate its activity. An example of this is the interaction of synuclein with synphilin that promotes its aggregation, the details of this interaction however are still not clear. Recent studies also suggest that a small protein GTPase rab3a is believed to be regulating the association of the protein to the membrane dependent on GTP, but the mechanism of this regulation is not unclear as the function of the α-synuclein is not totally understood. α-synuclein is also believed to have an impact on protein degradation, cytoskeletal interrelations and complex 1 inhibition in mitochondria inducing oxidative stress that results in neuronal death. It also plays an important role in regulation of dopamine neurotransmission. Therefore, owing to the role that this protein plays, especially in neurodegenerative disorders, various therapeutic measures related to this protein are being studied.<ref>doi: 10.1101/cshperspect.a009399</ref> | Besides being of key importance in reducing the degeneration caused due to the loss of CSPα, the α-synuclein is also believed to be related to various other proteins that regulate its activity. An example of this is the interaction of synuclein with synphilin that promotes its aggregation, the details of this interaction however are still not clear. Recent studies also suggest that a small protein GTPase rab3a is believed to be regulating the association of the protein to the membrane dependent on GTP, but the mechanism of this regulation is not unclear as the function of the α-synuclein is not totally understood. α-synuclein is also believed to have an impact on protein degradation, cytoskeletal interrelations and complex 1 inhibition in mitochondria inducing oxidative stress that results in neuronal death. It also plays an important role in the regulation of dopamine neurotransmission. Therefore, owing to the role that this protein plays, especially in neurodegenerative disorders, various therapeutic measures related to this protein are being studied.<ref>doi: 10.1101/cshperspect.a009399</ref> | ||
Revision as of 19:28, 17 January 2020
| This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115. |
To get started:
More help: Help:Editing |
α-synuclein
| ||||||||||||
References
- ↑ Stefanis L. alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012 Feb;2(2):a009399. doi:, 10.1101/cshperspect.a009399. PMID:22355802 doi:https://dx.doi.org/10.1101/cshperspect.a009399